BCL-2 Expression as a Predictive Marker of Hormone-Refractory Prostate Cancer Treated With Taxane-Based Chemotherapy

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-06-0147
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Taxane Chemotherapy for Hormone-Naïve Prostate Cancer With Its Expanding Role as Breakthrough Strategy

Frontiers in Oncology
Cancer ResearchOncology
2016English

Achieving Treatment Goals for Hormone-Refractory Prostate Cancer With Chemotherapy

Oncologist
Cancer ResearchMedicineOncology
2005English

Is BCL-2 a Predictive Marker of Neoadjuvant Chemotherapy Response in Patients With Urothelial Bladder Cancer Undergoing Radical Cystectomy?

Scandinavian Journal of Urology
UrologyNephrology
2019English

Hormone-Refractory Prostate Cancer

English

BRCA1 mRNA Expression as a Predictive and Prognostic Marker in Advanced Esophageal Squamous Cell Carcinoma Treated With Cisplatin- Or Docetaxel-Based Chemotherapy/Chemoradiotherapy

PLoS ONE
Multidisciplinary
2013English

PSA Levels and Prognosis in Patients With Hormone-Refractory Prostate Cancer Treated With Low-Dose Dexamethasone

Japanese Journal of Urology
Urology
2001English

Therapeutic Approach to Hormone-Refractory Prostate Cancer

Oncology & Hematology Review (US)
2007English

Article on BCL-2 as a Prognostic Marker

Clinical Cancer Research
Cancer ResearchOncology
2006English

ERCC1 Expression as a Predictive Marker of Squamous Cell Carcinoma of the Head and Neck Treated With Cisplatin-Based Concurrent Chemoradiation

British Journal of Cancer
Cancer ResearchOncology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy